BNP Paribas Asset Management’s Theravance Biopharma TBPH Stock Holding History

BNP Paribas Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Buy	61,132 +59,996	+5,281%	+$993K	﹤0.01%	1208
2026 Q1	$18.4K	Buy	+1,136	New	+$20.1K	﹤0.01%	2064
2018 Q3	–	Sell	-238,015	Closed	-$5.4M	–	949
2018 Q2	$5.4M	Buy	238,015 +15,032	+7%	+$357K	0.05%	463
2018 Q1	$5.41M	Buy	222,983 +46,791	+27%	+$1.29M	0.05%	466
2017 Q4	$4.91M	Buy	176,192 +1,368	+0.8%	+$40.5K	0.04%	491
2017 Q3	$5.99M	Buy	174,824 +12,069	+7%	+$395K	0.05%	449
2017 Q2	$6.48M	Buy	+162,755	New	+$6.26M	0.06%	437

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BNP Paribas Asset Management's TBPH Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Theravance Biopharma (TBPH) stake by 5,281% in Q2 2026, buying an estimated $993K and bringing the position to 61,132 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1208.

BNP Paribas Asset Management first reported a position in TBPH in Q2 2017 and has held it in 7 quarters since. The position peaked at $6.48M in Q2 2017. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

BNP Paribas Asset Management held 61,132 shares of Theravance Biopharma worth $1.04M as of Q2 2026.
BNP Paribas Asset Management bought 59,996 Theravance Biopharma shares in Q2 2026, an estimated $993K.
Theravance Biopharma made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1208 holding.
BNP Paribas Asset Management first reported a position in Theravance Biopharma in Q2 2017 and has held it in 7 quarters since.
BNP Paribas Asset Management's Theravance Biopharma position peaked at $6.48M in Q2 2017.
180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.